AstraZeneca PLC's recently launched authorized generic for Farxiga (dapagliflozin) is intended to bolster US sales by reaching more price-sensitive patients, which could be particularly important in the next year and a half before the brand faces a potentially substantial price reduction in Medicare Part D.
Key Takeaways
-
AstraZeneca launched a Farxiga authorized generic in January that aims to capture additional market share.
AstraZeneca collaborator Prasco Laboratories, LLC introduced the authorized generic in January. AstraZeneca is not expecting other generic competitors to...






